---
title: "Opthea Secures Solvency with Successful DFA Settlement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253532149.md"
description: "Opthea Limited has successfully settled its Development Funding Agreement (DFA) with investors, issuing equity and making a one-time payment, which secures its solvency with approximately USD20 million in cash. This settlement helps the company avoid potential liabilities of up to USD680 million and lifts the suspension of its stock trading. Dr. Jeremy Levin will take on additional responsibilities as Chairman. The latest analyst rating for Opthea (AU:OPT) is a Buy with a price target of A$1.25, despite a year-to-date price performance of -25.93%."
datetime: "2025-08-18T23:58:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253532149.md)
  - [en](https://longbridge.com/en/news/253532149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253532149.md)
generator: "portal-rs"
---

# Opthea Secures Solvency with Successful DFA Settlement

### Elevate Your Investing Strategy:

-   Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Opthea ( (AU:OPT) ) just unveiled an announcement.

Opthea Limited announced a significant corporate update following the successful settlement of its Development Funding Agreement (DFA) with investors. The settlement involves issuing equity to investors and a one-time payment, ensuring Opthea remains solvent with approximately USD20 million in cash. This resolution allows Opthea to avoid potential liabilities of up to USD680 million and lifts the suspension of its stock trading. The company’s leadership will see changes, with Dr. Jeremy Levin taking on additional responsibilities as Chairman.

The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.

**More about Opthea** 

Opthea Limited operates in the biotechnology industry, focusing on the development of therapies for eye diseases. The company is primarily known for its work on treatments for wet age-related macular degeneration (AMD).

**YTD Price Performance:** -25.93%

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$738.8M

For an in-depth examination of OPT stock, go to TipRanks’ Overview page.

## Trending Articles:

-   “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
-   “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
-   “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money

Disclaimer & DisclosureReport an Issue

### Related Stocks

- [OPT.US](https://longbridge.com/en/quote/OPT.US.md)
- [OPT.AU](https://longbridge.com/en/quote/OPT.AU.md)
- [OPTEY.US](https://longbridge.com/en/quote/OPTEY.US.md)
- [CYVNY.US](https://longbridge.com/en/quote/CYVNY.US.md)

## Related News & Research

- [OPT: Revenue up 14.8% to £120.6m; PAM acquisition boosts scale; integration and synergies progressing](https://longbridge.com/en/news/296062303.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**